| Issuer | % of Class | Filed |
|---|---|---|
|
Neuphoria Therapeutics Inc.
13G
NEUP · 64136E102
|
5.8% |
10/5/2026
Event 9/30/2026
|
|
Psyence Biomedical Ltd.
13G
PBM · 74449F407
|
6.8% |
10/5/2026
Event 9/30/2026
|
|
Quantum Biopharma Ltd.
13G/A
Amendment 1
QNTM · 74764Y205
|
4.95% |
10/5/2026
Event 9/30/2026
|
|
Silo Pharma, Inc.
13G
SILO · 82711P300
|
6.7% |
7/8/2026
Event 6/30/2026
|
|
Trulieve Cannabis Corp.
13G
TRLV · 89788C104
|
6.3% |
7/8/2026
Event 6/30/2026
|
|
Quantum Biopharma Ltd.
13G
QNTM · 74764Y205
|
5.3% |
7/8/2026
Event 6/30/2026
|
|
Village Farms International, Inc.
13G/A
Amendment 1
VFF · 92707Y108
|
2.8% |
7/8/2026
Event 6/30/2026
|
|
Enveric Biosciences, Inc.
13G/A
Amendment 1
ENVB · 29405E208
|
1.7% |
1/5/2026
Event 12/31/2025
|
|
Invesco Exchange-Traded Fund Trust II
13G/A
Amendment 1
IDLV · 46138E230
|
0% |
10/3/2025
Event 9/30/2025
|
|
Enveric Biosciences, Inc.
13G
ENVB · 29405E208
|
6.3% |
10/3/2025
Event 9/30/2025
|
|
Village Farms International, Inc.
13G
VFF · 92707Y108
|
5.3% |
10/3/2025
Event 9/30/2025
|
|
Clearmind Medicine Inc.
13G/A
Amendment 1
CMND · 185053402
|
4.8% |
7/3/2025
Event 6/30/2025
|
|
Invesco Exchange-Traded Fund Trust II
13G
IDLV · 46138E230
|
9.7% |
7/3/2025
Event 6/30/2025
|
|
InMed Pharmaceuticals Inc.
13G/A
Amendment 1
INM · 457637601
|
0% |
4/2/2025
Event 3/31/2025
|
|
Enveric Biosciences, Inc.
13G/A
Amendment 1
ENVB · 29405E208
|
3.7% |
4/2/2025
Event 3/31/2025
|
|
Lucy Scientific Discovery, Inc.
13G/A
Amendment 1
LSDIF · 54960E203
|
0% |
4/2/2025
Event 3/31/2025
|
|
Psyence Biomedical Ltd.
13G/A
Amendment 1
PBM · 74449F209
|
0.8% |
1/6/2025
Event 12/31/2024
|
|
Enveric Biosciences, Inc.
13G
ENVB · 29405E208
|
5.9% |
1/6/2025
Event 12/31/2024
|
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.